Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23–6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates

This publication has 12 references indexed in Scilit:

• Interlaboratory variations of fluoroquinolone susceptibility testing: An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials
  Diagnostic Microbiology and Infectious Disease, 1993
• Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-μg disks
  Diagnostic Microbiology and Infectious Disease, 1992
• Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628
  Diagnostic Microbiology and Infectious Disease, 1991
• In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391
  Diagnostic Microbiology and Infectious Disease, 1991
• Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates
  Antimicrobial Agents and Chemotherapy, 1991
• Fluoroquinolone Antimicrobial Agents
  New England Journal of Medicine, 1991
• RO 23-6240 (AM-833), a new fluoroquinolone: In vitro antimicrobial activity and tentative disk diffusion interpretive criteria
  Diagnostic Microbiology and Infectious Disease, 1987
• In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
  Antimicrobial Agents and Chemotherapy, 1986
• In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone
  Antimicrobial Agents and Chemotherapy, 1986
• Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria
  Antimicrobial Agents and Chemotherapy, 1984